Oncology remains the highest revenue-generating therapy area in global pharma — and the gap between it and everything else keeps widening. Immunotherapy and targeted therapies are dominating the top of the list, and that trend is not slowing down. At the same time, the pressure is building. Biosimilars are coming for the older assets. Next-generation therapies, ADCs, bispecifics, cell therapies, are entering the mix. The competitive dynamics are getting more complex every year. More Info: https://clival.com/blog/10-best-selling-cancer-drugs-by-estimated-global-sales-2025-2026